RETINA-AI Health company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Series A | Alive

Total Raised


Last Raised

$5.2M | 2 yrs ago

About RETINA-AI Health

RETINA-AI Health develops artificial intelligence software for diagnosing Retinal and Systemic Diseases from images of the retina.

RETINA-AI Health Headquarter Location

2925 Richmond Ave, Ste 1200

Houston, Texas, 77098,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing RETINA-AI Health

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned RETINA-AI Health in 1 CB Insights research brief, most recently on Aug 13, 2020.

Expert Collections containing RETINA-AI Health

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

RETINA-AI Health is included in 6 Expert Collections, including Artificial Intelligence.


Artificial Intelligence

9,093 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.


Medical Devices

8,442 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health Monitoring & Diagnostics

2,707 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance



1,750 items


Digital Health

13,075 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)


Health IT

10,939 items

This collection includes public and private companies, as well as startups, that market software solutions to healthcare provider organizations.

RETINA-AI Health Patents

RETINA-AI Health has filed 4 patents.

The 3 most popular patent topics include:

  • Diseases of the eye and adnexa
  • Classification algorithms
  • Dosage forms
patents chart

Application Date

Grant Date


Related Topics




Machine learning, Artificial intelligence, Rare diseases, Classification algorithms, Diseases of the eye and adnexa


Application Date


Grant Date



Related Topics

Machine learning, Artificial intelligence, Rare diseases, Classification algorithms, Diseases of the eye and adnexa



Latest RETINA-AI Health News

Autonomous Diabetic Retinopathy Screening Device Yields Positive Results

Jan 4, 2022

Autonomous Diabetic Retinopathy Screening Device Yields Positive Results The product has been submitted to the FDA for review. PR Newswire01.04.22 RETINA-AI Health Inc.  has announced positive results from the pivotal study of the RETINA-AI Galaxy, a multi-device compatible autonomous diabetic retinopathy screening device intended for use in primary care settings. Furthermore, the company has submitted its application to the U.S. Food and Drug Administration (FDA) for clearance. The pivotal clinical study results were presented at the Society for Imaging Informatics in Medicine (SiiM)'s Conference on Machine Intelligence in Medical Imaging (CMIMI21). The multi-center, multi-device observational study recruited subjects from four primary care sites. Clinical performance of the RETINA-AI Galaxy software as a medical device (SaMD) was assessed on five robotic fundus cameras: CenterVue DRSPlus, Crystalvue NFC-700, NextSight Nexy, Topcon NW400, and CenterVue DRS. These five studies, one per camera, were run in parallel. For each camera, 397 subjects aged 22 years or above and who had diabetes were recruited. All data was prospectively obtained. Intent to screen ranged from 383-385 depending on camera. Primary endpoints were sensitivity and specificity of more than mild diabetic retinopathy (mtmDR) and sensitivity and specificity of vision threatening diabetic retinopathy (vtDR). mtmDR was denoted as Early Treatment of Diabetic Retinopathy Severity Scale (ETDRS) ≥35 (but not 90) and/or Clinically Significant Diabetic Macula Edema (CSDME). vtDR was denoted as ETDRS ≥53 (but not equal to 90) and/or CSDME. Grading was done by American Board Certified ophthalmologists who are fellowship trained in retina (retina specialists) at the Retina Reading Center (RRC). A probabilistic grading schema based on level of agreement amongst graders was used to quantify grades. And a declarative assignment of mtmDR := Probable mtmDR and vtDR := possible vtDR was used. A blinded assessment was conducted as was computation of the Receiver Operator Characteristic (ROC) curves. For mtmDR, sensitivity of the RETINA-AI Galaxy at or above 82.5 percent specificity was as follows: On DRSPlus, sensitivity = 95 percent and specificity = 82.8 percent On Crystalvue NFC700, sensitivity = 89.2 percent and specificity = 82.5 percent On Nexy, sensitivity = 83.6 percent and specificity = 82.6 percent On Topcon NW400, Sensitivity = 87.3 percent and specificity = 83.2 percent On DRS, Sensitivity 88.2 percent and specificity = 85.3 percent For vtDR, sensitivity of the RETINA-AI Galaxy at or above 82.5 percent specificity was as follows: On DRSPlus, sensitivity = 97.1 percent, specificity = 84 percent On Crystalvue NFC-700, sensitivity = 88.2 percent, specificity = 88.1 percent On Nexy, sensitivity 94.1 percent, specificity 90.9 percent On Topcon NW400, sensitivity = 93.9 percent, specificity 94.8 percent On DRS, sensitivity = 94.1 percent and specificity = 85 percent Imageability was 99.2 percent on the DRSPlus, Crystalvue NFC-700, and Nexy; 96.5 percent on the Topcon NW400, and 94 percent on the DRS. All primary endpoints were met. The RETINA-AI Galaxy device attained a sensitivity was 100 percent on all five cameras for definite mtmDR, probable vtDR, and vtDR in the absence of CSDME, each with specificity at or above 82.5 percent. Dr. Stephen G. Odaibo, RETINA-AI Health Inc.'s founder and CEO, himself a computer scientist, AI/ML expert, and retina specialist, stated that "Diabetes affects over 35 million Americans and 450 million people globally. And each diabetic patient requires an annual eye exam, but most do not receive it due to multiple factors. Artificial Intelligence can play a significant role in increasing access to care, but till now there has been a serious lack of fundus camera options that have undergone rigorous validation for use as accessories to autonomous AI systems. This is the first such study that assesses an autonomous AI system on cameras from multiple manufacturers." RETINA-AI Health Inc. is a privately-held Delaware C-Corp founded in 2017 and headquartered in Houston Texas. The company is focused on building AI to transform healthcare and improve the outcomes of prevalent chronic diseases. It develops and deploys retina-based AI for detection of systemic chronic diseases at scale. Related Breaking News PR Newswire 01.04.22 Sam Brusco, Associate Editor 01.04.22 PR Newswire 01.04.22 Globe Newswire 01.04.22 Sam Brusco, Associate Editor 01.04.22 Audax Private Equity 01.04.22 Sam Brusco, Associate Editor 01.03.22 RQM+ 01.03.22 Firstronic 01.03.22 Sam Brusco, Associate Editor 01.03.22 PR Newswire 01.03.22 GlobeNewswire 01.03.22 NextGen Healthcare 01.03.22 Globe Newswire 01.03.22 PR Newswire 01.03.22

RETINA-AI Health Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

RETINA-AI Health Rank

  • When was RETINA-AI Health founded?

    RETINA-AI Health was founded in 2017.

  • Where is RETINA-AI Health's headquarters?

    RETINA-AI Health's headquarters is located at 2925 Richmond Ave, Ste 1200, Houston.

  • What is RETINA-AI Health's latest funding round?

    RETINA-AI Health's latest funding round is Series A.

  • How much did RETINA-AI Health raise?

    RETINA-AI Health raised a total of $10.4M.

  • Who are the investors of RETINA-AI Health?

    Investors of RETINA-AI Health include Bill Smith and CrossCut Ventures.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.